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Abstract
Background: Neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) has been a
standard treatment option for locally advanced rectal cancer with improved local control. However, systemic
recurrence despite neoadjuvant CRT remained unchanged. The only significant prognostic factor proven to be
important was pathologic complete response (pCR) after neoadjuvant CRT. Several efforts have been tried to
improve survival of patients who treated with neoadjuvant CRT and to achieve more pCR including adding
cytotoxic chemotherapeutic agents, chronologic modification of chemotherapy schedule or adding chemotherapy
during the perioperative period. Consolidation chemotherapy is adding several cycles of chemotherapy between
neoadjuvant CRT and TME. It could increase pCR rate, subsequently could show better oncologic outcomes.
Methods: Patients with advanced mid or low rectal cancer who received neoadjuvant CRT will be included after
screening. They will be randomized and assigned to undergo TME followed by 8 cycles of adjuvant chemotherapy
(control arm) or receive 3 cycles of consolidation chemotherapy before TME, and receive 5 cycles of adjuvant
chemotherapy (experimental arm). The primary endpoints are pCR and 3-year disease-free survival (DFS), and the
secondary endpoints are radiotherapy-related complications, R0 resection rate, tumor response rate, surgery-related
morbidity, and peripheral neuropathy at 3 year after the surgery. The authors hypothesize that the experimental
arm would show a 15% improvement in pCR (15 to 30%) and in 3-year DFS (65 to 80%), compared with the control
arm. The accrual period is 2 years and the follow-up period is 3 years. Based on the superiority design, one-sided
log-rank test with α-error of 0.025 and a power of 80% was conducted. Allowing for a drop-out rate of 10%, 358
patients (179 per arm) will need to be recruited. Patients will be followed up at every 3 months for 2 years and
then every 6 months for 3 years after the last patient has been randomized.
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Discussion: KONCLUDE trial aims to investigate whether consolidation chemotherapy shows better pCR and 3-year
DFS than adjuvant chemotherapy alone for the patients who received neoadjuvant CRT for locally advanced rectal
cancer. This trial is expected to provide evidence to support clear treatment guidelines for patients with locally
advanced rectal cancer.
Trial registration: Clinicaltrials.gov NCT02843191 (First posted on July 25, 2016).
Keywords: Rectal cancer, Chemoradiotherapy, Consolidation chemotherapy, Pathologic complete response, Disease
free survival
Background
Neoadjuvant chemoradiotherapy (CRT) followed by total
mesorectal excision (TME) is the standard treatment for
local advanced mid- or low rectal cancer [1, 2]. Reduction
of local recurrence has been proven after introduction of
TME for rectal cancer [3]. Additionally, chemotherapy
and/or radiotherapy have shown the roles to improve
oncologic outcomes by controlling local recurrence. Pre-
operative chemoradiotherapy showed better outcomes
compared with postoperative chemoradiotherapy or pre-
operative radiotherapy alone [4–8].
However, failure of systemic controls including liver,
lung, peritoneum, or bone still remained even after CRT
followed by TME [1, 4, 5]. Many efforts have been made
to control micrometastatic disease and to prevent distant
and local recurrence. So far, no reliable molecular or
pathologic biomarkers to foster pathologic complete
response (pCR), which means complete regression of the
tumor after radiotherapy and/or chemotherapy, was iden-
tified. Meanwhile, patients who showed pCR have been re-
ported with lower recurrence and better survival [9, 10].
Therefore, many trials have been performed to increase
pCR rates by changing perioperative treatment strategies.
Prolongation of the interval between CRT and TME has
shown to increase pCR rates [11]. The interval has pro-
longed recently from 6 to 8 weeks up to 12 weeks, and sev-
eral authors reported that extending the interval showed
better pCR rates without increasing morbidity. [12–15] An-
other tries to achieve more pCR were adding platinum
analogue (i.e. oxaliplatin) or vascular endothelial growth fac-
tor antagonist (i.e. bevacizumab) preoperatively and/or post-
operatively based on 5-FU [16–18]. Unfortunately most of
them failed to show higher pCR rates but increased acute
toxicity [19, 20]. Recent trials reported that changing se-
quence of chemotherapy cycles as well as chemotherapeutic
agents would attain better pCR rates, and new trials are
launching. The examples are induction chemotherapy, con-
solidation chemotherapy, and sandwich regimen (prior to,
concurrently with, and following radiation therapy) [21–26].
Sandwich regimen with capecitabine and oxaliplatin accom-
panied by 25 Gy of radiotherapy resulted in 42.2% of pCR
rates, and even 10% of patients needed no surgery because
the patients had achieved clinical complete response [22].
Garcia-Aguilar et al. reported that pCR rates were
significantly increased in the patients who received
various cycles of consolidation chemotherapy of FOL-
FOX regimen without significantly increased toxicity
[21]. Then they showed that additional consolidation
chemotherapy resulted in higher pCR rates in their
multicenter, phase 2 trial [23]. However, it is not
sufficient to conclude that consolidation chemother-
apy is the only affecting factor to pCR due to several
limitations. The interval and duration of consolidation
chemotherapy were variable from 6 to 20 weeks.
Moreover, adjuvant chemotherapy after TME followed
by CRT was not standardized, and the total doses or
cycles of chemotherapy was not consistent equally.
Therefore, well-designed randomized controlled trials
to assess the effect of consolidation chemotherapy
alone after neoadjuvant chemoradiotherapy for locally
advanced mid or low rectal cancer is required.
Methods/design
Study design
This trial is a phase 3 trial investigating the efficacy of
3 cycles of consolidation chemotherapy between neoad-
juvant CRT and TME for locally advanced rectal cancer.
To prove the effects of consolidation chemotherapy, we
will administer the equal schedules of chemotherapy
(8 cycles of mFOLFOX6 chemotherapy) in both groups.
Patient selection criteria are as follows:
– Inclusion Criteria
1) An adult aged 20-75 years old
2) Histologically confirmed adenocarcinoma of mid or
low rectum (i.e. the lower margin of tumor located
below the peritoneal reflection or within 12 cm
from the anal verge by digital rectal examination,
rigid proctosigmoidoscopy or MRI measurement
from sagittal T2 weighted image)
3) Locally advanced rectal cancer confirmed by
magnetic resonance image (MRI): Clinical stage
T1-3N1or2 or clinical stage cT3N0 (or depth of
perirectal invasion by tumor > 5 mm on MRI), or
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suspicious of circumferential invasion on MRI
(or circumferential margin < 1 mm)
4) ECOG performance status of 0-2
5) ASA score of ≤ 3
6) An informed consent form has been signed by the
patient.
– Exclusion Criteria
1) Upper rectal cancer (i.e. the lower margin of tumor
located above the peritoneal reflection)
2) Clinical stage T1or2N0 on MRI
3) Clinical stage T4Nany on MRI (T4 lesion would be
complicated to manage)
4) Distant metastasis diagnosed by imaging diagnosis
or histology
5) The patient received chemotherapy or radiotherapy
during the past 6 months
6) The patient received any therapy for colorectal
cancer or another malignancy during the past 5 years
7) The patient has severe underlying diseases or poor
condition to receive chemotherapy or radiotherapy
8) Pregnant of breastfeeding women
9) The patient who participate in another clinical trial,
or receives any drug for the trial
10) Uncontrolled peripheral neuropathy (> Grade 2)
11) Any unhealed wound, fracture, peptic ulcer, or
intraabdominal abscess
12) Active gastrointestinal bleeding
13) Patients with an active infection, which needs
antibiotic therapy, during the randomization period
All the patients who received CRT (50.4 Gy radiation
with capecitabine 825 mg/m2 twice daily for 28 days) will
be randomized in a 1:1 ratio into one of the following
arms after screening: conventional chemotherapy group
(control arm: Arm 1) or consolidation chemotherapy
group (experimental arm: Arm 2) (Fig. 1). Stratification
factors are age (< 70 or ≥ 70), clinical T stage (T1/2 or T3),
and clinical N stage (N0 or N1/2). All eligible patients will
be enrolled from approval of institutional review board
(IRB) at each participating institution. The accrual period
is 2 years and the follow up period is 3 years. The
screening program includes history taking, physical
examinations, laboratory tests, chest X-ray, EKG, and so
on. If abnormal results requiring treatment were found
within the screening, the patient will be given a proper
treatment and the enrollment can be cancelled.
Arm 1 (conventional chemotherapy group): the patients,
who are allocated to the arm 1, will undergo TME at
Fig. 1 Flowdiagram of the trial
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9 weeks after the CRT. They will receive 8 cycles of
adjuvant chemotherapy with mFOLFOX6 (5-fluorouracil
with Oxaliplatin) every 2 weeks within 6 weeks after TME.
Arm 2 (consolidation chemotherapy group); the patients,
who are allocated to the arm 2, will receive 3 cycles of
mFOLFOX6 every 2 weeks after neoadjuvant CRT, and
undergo TME at 9 weeks after the CRT. Then patients
will receive the additional 5 cycles of adjuvant chemother-
apy with mFOLFOX6 within 6 weeks after TME.
TME is intended to obtain a complete resection of the
tumor (R0) with negative resection margins and ad-
equate lymphadenectomy. The surgeon can decide
stoma formation, medial-to-lateral or lateral-to-medial
approach, vascular ligation (i.e. high tie or low tie),
splenic flexure mobilization as well as the method of
operation including open, laparoscopic, or robotic sur-
gery. A complete resection (R0) or microscopic remnant
resection (R1) should be confirmed by pathologists after
TME. Patient with visible incomplete resection (R2) or
distant metastasis is excluded in this study.
mFOLFOX6 regimen is composed of levoleucovorin
(200 mg/m2) or leucovorin (400 mg/m2), oxaliplatin
(85 mg/m2) for 2 h, then 5-FU (400 mg/m2) bolus followed
by 5-FU (2400 mg/m2) for 46 h. All chemothrapy-related
adverse events will be checked every cycle. Patients older
than 70 years will receive chemotherapy as 75% reduced
dose for the safety. [27–29] When the absolute neutrophil
count decreased less than 1500/μl or any drug-related ad-
verse effects of grade 3 were noted, dose reduction or delay
of chemotherapy will be considered. However, delay of
chemotherapy does not mean delay of TME in Arm 2. Even
though a patient in Arm 2 lacks one or two cycles of con-
solidation chemotherapy due to chemotherapy-related ad-
verse events, the patient will underwent TME at 9 weeks
after CRT, and the data will be analyzed as intention-to-
treat. All patients will equally visit every 3 months for
2 years, and then every 6 months for 3 years. Physical
examination and laboratory test will be performed every
3 months, abdominal-pelvic CT scan every 6 months, chest
CT every 1 year, and colonoscopy will be performed at 1
and 5 years to detect metastasis or recurrence.
Objective
The authors will compare pCR rates and 3-year disease-
free survival (DFS) rates as the primary endpoints between
the two groups. pCR is defined no residual tumor or
complete replacement of fibrosis in the surgical specimen
(i.e. Mandard 1 or Dworak 4). 3-yr DFS is defined as pro-
portion of the patients who survive without any local or
distant recurrence/metastasis at the 3 years of follow up.
Secondary endpoints are radiotherapy-related toxicity,
R0 resection rate, tumor response rate, surgery-related
morbidity, and severity of peripheral neuropathy at
3 years. Acute and chronic toxicity will be recorded in
the electronic case report form (eCRF). R0 resection rate
is defined as the proportion of R0 resection among all
TME specimens according to the pathologic results.
TME quality evaluation will be performed by surgeons
or pathologists: complete, nearly complete, and incom-
plete [30]. Tumor response rate is represented as grade
of Mandard or Dworak [31, 32]. Postoperative complica-
tion within 30 days after TME will be recorded accord-
ing to the grade of Clavien-Dindo classification of
surgical complications [33]. Severity of peripheral neur-
opathy will be assessed at 3 years as well as every cycles
of chemotherapy. The grade of any adverse event will be
recorded by Common Terminology Criteria for Adverse
Events (CTCAE) 4.0 [34]. Operative, pathologic, and
chemotherapeutic reports are documented in the eCRF.
Sample size calculation and randomization
Based on literatures, pCR rates and 3-year DFS after CRT
for rectal cancer were known to be 10 to 28% and 50-65%,
respectively [2, 6, 8–13]. Thus we hypothesize that the ex-
perimental arm would show a 15% improvement in pCR
and in 3-year DFS, compared with the control arm (15 to
30% and 65 to 80%, respectively). The accrual period is
2 years and the follow-up period is 3 years. Based on the
superiority design, one-sided proportion test and log-rank
test with α-error of 0.025 and a power of 90% was con-
ducted for both primary endpoints: pCR and 3-year DFS.
The pCR of each group was considered to be 15 and 30%,
and the 3-year DFS of each group was considered to be 65
and 80% assuming that accrual time was 2 years and follow
up time was 3 years. Allowing neoadjuvant CRT for a drop-
out rate of 10%, 358 patients (179 per arm) for pCR and
316 patients (158 per arm) for 3-year DFS will need to be
recruited. Therefore a total of 358 participants (among 358
and 316) are needed. This study of 358 participants had at
least 81% power (90% each = 0.9, so 0.9 × 0.9 = 0.81) to sim-
ultaneously detect a difference of pCR and 3-year DFS of
two groups. Randomization will be performed in a 1:1 ratio
by computer-generated random numbers, with the use of
stratified permuted 4 blocks. It will stratified accord-
ing to age (< 70 vs. ≥70), clinical T stage (T1/2 or T3),
and clinical N stage (N0 or N1/2). Among 8 strata, 2
strata will not be used because clinical T1/2 N0 (age < 70
and ≥ 70) are not indicated for neoadjuvant CRT.
Data collection and management
The authors employ a web-based clinical research manage-
ment system (Healthroad, Seoul, Republic of Korea), which
gathers clinical data and information through on-line
(konclude.e-trial.co.kr, Fig. 2). Principal investigators or
clinical research coordinators in each site should sign up
and enter clinical data onto an eCRF. Approved re-
searchers of central data managing institution will manage
the data and information. Only the principal investigator
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can access the final trial dataset and analyze them. Per-
sonal information of enrolled patients will be maintained
for 5 years in order to protect confidentiality.
Drop-out
A patient can be dropped out in cases as follows:
1) Not acceptable adverse events related to surgery or
chemotherapy
2) Different treatment needs which not approved in
this trial
3) A patient’s refusal by any reasons
4) A patient’s pregnancy
Statistical analysis
Continuous variables will be analyzed with independent
two sample t-test, whereas categorical variables will be
analyzed with Chi-square test or Fisher’s exact test. 3-yr
DFS will be analyzed with Kaplan-Meier curve. The dif-
ference between both Arms will be compared by Cox’s
proportional hazards model. Interim analysis for pCR
will be performed after TME of the last enrolled patient
with Cochran-Mantel-Haenszel test. P-value less than
0.05 will be considered as significant. All analyses will
be performed with SPSS version 20.0.
Safety evaluation and reporting of adverse effect
Adverse events and serious adverse events must be re-
ported to protect patients. Radiotherapy-related toxicity,
chemotherapy-related toxicity, and surgery-related mor-
bidity will be recorded onto the eCRF. Serious adverse
events will be reported every quarter of the year, whereas
suspected, unexpected, serious, adverse reaction, which
could result in death or life threatening, will be reported
within 15 days from the detection by investigators.
Data monitoring
A committee will be organized for trial supervision. All
members of the committee are certified according to the
course of good clinical practice in each institution. All
process including data collection, record, and manage-
ment will be monitored by them. The committee can
advise and request the principal investigator to change
some plans.
Protocol modification
If needed, the protocol can be modified by communica-
tion and agreement of the principal investigator and trial
participants with revising its version.
Fig. 2 The electronic case report form on line
Table 1 pCR by adding Oxaliplatin to 5-FU for rectal cancer
Trial N Regimen pCR rate
STAR-01 705 5-FU vs. 5-FU + Oxaliplatin 16% vs. 16% (p = 0.904)
ACCORD 12 598 Capecitabine vs. CAPOX 13.9% vs. 19.2% (p = 0.09)
NSABP R-04 1608 5-FU vs. 5-FU + Oxaliplatin vs. Capecitabine vs. CAPOX 17.8% vs. 19.5% (p = 0.42)
CAO/ARO/AIO-04 1236 5-FU vs. 5-FU + Oxaliplatin 13% vs. 17% (p = 0.031)
PETACC-6 1094 Capecitabine vs. CAPOX 11.3% vs. 13.3% (p = 0.31)
Dellas et al. 70 CAPOX + Bevacizumab 17.4%
EXPERT-C 165 CAPOX vs CAPOX + Cetuximab 7% vs. 11% (p = 0.714)
pCR pathologic complete response, 5-FU 5-fluorouracil, CAPOX capecitabine with oxaliplatin
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Discussion
Despite fundamental role of 5-FU as neoadjuvant and ad-
juvant regimen for advanced colorectal cancer, addition of
various cytotoxic agents has been tried to improve onco-
logic outcomes. Among them was oxaliplatin, a platinum
analogue (Table 1). FOLFOX as adjuvant regimen for
locally advanced rectal cancer showed superior DFS
compared with 5-FU or capecitabine alone in ADORE
trial and the German CAO/ARO/AIO-04 study [35, 36],
although it failed to show better oncologic outcomes but
more proportion of acute toxicity as neoadjuvant regimen
[7, 17, 18]. Surgical and medical oncologists concluded
that FOLFOX is only efficient as adjuvant setting, not neo-
adjuvant for rectal cancer. Then, can FOLFOX show
higher pCR rates without increasing acute toxicity in the
position between neoadjuvant and adjuvant? This is the
point that KONCLUDE trial concentrates on.
As aforementioned, several authors already reported
high pCR rates from consolidation chemotherapy with-
out significantly increasing toxicity, while a couple of
trials are on-going [21–25]. However, there were a few,
but meaningful limitations in their studies including
characters of phase 2 trial, variation of the resting period
between radiotherapy and TME, and difference of total
cycles of chemotherapy. These studies cannot establish
the treatment guideline because of their inherited bias.
Therefore, we adjusted total cycles of chemotherapy as
8 cycles of mFOLFOX6 to avoid inherited bias due to
different cycles of chemotherapy. Moreover, we fixed the
interval between radiotherapy and TME as 9 weeks, ac-
cording to previous literatures which commented appro-
priate resting period as 6 to 12 weeks, to investigate
efficacy of consolidation without confounding of various
duration of interval from completion of CRT to TME.
KONCLUDE trial started with the first enrollment in
December 7, 2016 after the registration on clinicaltrials.
gov in July 25, 2016 (NCT02843191). We expect that
this trial will conclude whether consolidation chemo-
therapy would attain higher pCR and improved DFS or
not, providing a critical clue to establish the standard
treatment in locally advanced mid- or low rectal cancer
with level 1 evidence.
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